Functional genomics studies have leveraged CRISPR-Cas9 to knock out FGFR4, resulting in enhanced sensitivity of HCC cells to sorafenib-induced ROS generation and apoptosis, a phenotype also observed with FGF19 knockout 284. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.